Loading clinical trials...

Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain

Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain: Predictors of Response - a Randomised, Double-blind, Placebo-controlled Clinical Trial

NCT01302275•Søren H. Sindrup

View on ClinicalTrials.gov

Summary

The purpose of this trial is to determine if the effect of oxcarbazepine on chronic peripheral nerve pain depends on the supposed mechanism of the pain, ie. if oxcarbazepine mainly relieve pain in patients with irritable nerves.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•age \> 18 years old
•definite or probable neuropathic pain
•diagnosis of polyneuropathy, postherpetic neuralgia or peripheral nerve inju
•pain duration \> 3 months
•pain rating at baseline \>= 4 point NRS
•Informed consent

Exclusion Criteria

•other non-neuropathic pain condition
•allergy to oxcarbazepine
•renal or hepatic impairment
•epilepsy
•depression and other serious psychiatric disorders
•serious medical condition
•previous treatment for neuropathic that cannot be stopped
•pregnancy
•patients expected not to be able to comply with study protocol
•treatment with anticonvulsants, antidepressant or opioids

Locations (2)

Danish Pain Research Center, Aarhus University Hospital

Aarhus, Denmark

Department of Neurology, Odense University Hospital

Odense, Denmark

Key Dates

Start Date

February 1, 2011

Primary Completion Date

May 1, 2013

Completion Date

May 1, 2013

Last Updated

May 5, 2014

Enrollment

117

ACTUAL participants

Conditions

PolyneuropathyPeripheral Nerve InjuryPostherpetic Neuralgia

Interventions

Oxcarbazepine

DRUG

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06752356

Chronic Inflammatory Demyelinating Polyneuropathy

View study

RECRUITINGPHASE3

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT06920004

Chronic Inflammatory Demyelinating PolyneuropathyCIDP+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 5, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain

Inclusion Criteria

Exclusion Criteria

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Registry for Adults With Plasma Cell Disorders (PCD's)

Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function